SCHEMBL4353366

SCHEMBL4353366

Oc1c(Cl)cccc1NC(=S)NC1CCCCC1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.76
SMN1; SMN2 Q16637 3/20 0.76
POLB P06746 1/20 0.72
LMNA P02545 4/20 0.62
GAA P10253 2/20 0.62
ALOX12 P18054 2/20 0.62
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
NPSR1 Q6W5P4 4/20 0.60
MAPT P10636 3/20 0.60
CYP1A2 P05177 2/20 0.60
CYP2C19 P33261 2/20 0.60
NPC1 O15118 1/20 0.60
MAPK1 P28482 1/20 0.60
KDM4E B2RXH2 1/20 0.60
RAB9A P51151 1/20 0.60
HTT P42858 2/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6226175 0.85 SMN1; SMN2 (0.69) ALDH1A1SMN1; SMN2POLBLMNAGAA
SCHEMBL4354001 0.83 LMNA (0.62) ALDH1A1SMN1; SMN2POLBLMNAGAA
SCHEMBL4354614 0.83 RAB9A (0.76) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL4354694 0.80 MEN1 (0.68) ALDH1A1SMN1; SMN2POLBLMNAGAA
SCHEMBL4342275 0.80 SMN1; SMN2 (0.58) ALDH1A1SMN1; SMN2POLBLMNAALOX12
SCHEMBL4348625 0.75 SMN1; SMN2 (0.71) ALDH1A1SMN1; SMN2POLBLMNAGAA
SCHEMBL4357795 0.74 LMNA (0.79) ALDH1A1SMN1; SMN2LMNAGAAALOX12
SCHEMBL4347651 0.74 MAPT (0.72) ALDH1A1SMN1; SMN2POLBLMNAGAA
SCHEMBL4341453 0.74 POLB (0.60) ALDH1A1SMN1; SMN2POLBLMNAGAA
SCHEMBL4349380 0.74 MEN1 (0.59) ALDH1A1SMN1; SMN2POLBLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 ALDH1A1 2565/4885SMN1; SMN2 1791/4885POLB 3571/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 ALDH1A1 2767/4885SMN1; SMN2 3250/4885POLB 2402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.